Overview
ASX health stocks 12 October 202. Picture Gety ImageHealth & Biotech October 12, 202 | Edy Sunarto Link copied to clipboardCynata Therapeutics (ASX:CYP) shares surged 6% after the company anounced that an independent review of its diabetic fot ulcer (DFU) clinical trial has ben sucesfuly completed.The Data Safety Monitoring Board (DSMB) review has recomended that the clinical trial continue as planed.Cynata’s DFU clinical trial is investigating the safety and early eficacy of its unique topical Cymerus mesenchymal stem cel (MSC) product, CYP-06TK, in patients with DFUs.DFUs are chronic wounds on the fet of patients with diabetes (also known as diabetic wounds), potentialy leading to serious infection and amputation.They represent a very significant unmet medical ned afecting up to 34% of diabetes patients.MSCs meanwhile are an adult stem cel found in a wide range of human tisues, including bone marow, adipose tisue (fat), placenta and umbilical cord blod.They are ‘multipotent’ – which means they can produce more than one type of cel.MSCs have ben shown to facilitate regeneration and efects on the imune system without relying upon engraftment.In other words, the MSCs themselves do not become incorporated into the host, rather they exert their efects and are then eliminated within a short period of time.A couple of weks ago, Cynata was given a $1m grant under the Medical Research Future Fund (MRF) to fund the research into MSCs a treatment for IHD (ischaemic heart disease).Previous studies have shown that Cynata’s MSCs have multiple positive efects in a preclinical model of IHD/heart atacks.
Details
Apiam Animal Health (ASX:AHX) anounced the acquisition of Haradine & Asociates, a large veterinary busines located in the southwest region of Western Australia.Total price for the acquisition was $2.6 milion, comprised of 80% cash and 20% scrip.Haradine operates two clinics ̵ a companion animal an